Table 1 Baseline characteristics of the studies included in the network Meta-analysis
Source | Registered ID(date) | Phase | Treatment | Participants | EFS median,95%CI Months | HR (95%CI) | PCR No./total (%) | MPR No./total (%) | Grade ≥ 3AEs No./total (%) | Rates of undergoing surgery No./total (%) | R0 resection rate No./total (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Forde 2022 | NCT02998528 (2016) | III | Nivolumab Q3W plus ChemotherapyQ3W | 179 | 31.6 (30.2-NE) | 0.63 (0.43–0.91) | 43/179 (24.0) | 66/179 (36.9) | 59/176 (33.5) | 149/179(83.2) | 124/149(83.2) |
Chemotherapy Q3W | 179 | 20.8 (14.0−26.7) | 4/179 (2.2) | 16/179 (8.9) | 65/176 (36.9) | 135/179(75.4) | 105/135(77.8) | ||||
Provencio 2023 | NCT03838159 (2019) | II | Nivolumab Q3W plus Chemotherapy Q3W | 57 | NR | NR | 21/57 (36.8) | 30/57 (53.0) | 12/57 (21.1) | 53/57(93.0) | 50/53 (94.3) |
Chemotherapy Q3W | 29 | NR | 2/29 (6.9) | 4/29 (14.0) | 3/29 (10.3) | 20/29(69.0) | 17/20 (85.0) | ||||
John 2023 | NCT03800134 (2019) | III | Durvalumab Q3W plus Chemotherapy Q3W | 366 | NR (31.9-NE) | 0.68 (0.53–0.88) | 63/366 (17.2) | 122/366 (33.3) | 130/400 (32.4) | 284/366(77.6) | 269/284(94.7) |
Placebo plus Chemotherapy Q3W | 374 | 25.9 (18.9-NE) | 16/374 (4.3) | 46/374 (12.3) | 131/398 (32.9) | 287/374(76.7) | 262/287(91.3) | ||||
Shun 2023 | NCT04158440 (2019) | III | Toripalimab Q3W plus Chemotherapy Q3W | 202 | NR (24.4-NE) | 0.40 (0.28–0.57) | 50/202 (24.8) | 98/202 (48.5) | 157/202 (77.7) | 166/202(82.2) | 159/166(95.8) |
Placebo plus Chemotherapy Q3W | 202 | 15.1 (10.6–21.9) | 2(1.0) | 17/202 (8.4) | 113/202 (55.9) | 148/202(73.3) | 137/148(92.6) | ||||
Lei 2022 | NCT04338620 (2020) | II | Camrelizumab Q3W plus Chemotherapy Q3W | 43 | NR (NE-NE) | 0.52 (0.21–1.29) | 14/43 (32.6) | 28/43 (65.1) | 11/43 (25.6) | 40/43(93.0) | 37/40(92.5) |
Chemotherapy Q3W | 45 | NR (NE-NE) | 4/45 (8.9) | 7/45 (15.6) | 5/45 (11.1) | 42/45(93.3) | 36/42(85.7) | ||||
Wakelee 2023 | NCT03425643 (2018) | III | Pembrolizumab Q3W plus Chemotherapy Q3W | 397 | NR (34.1-NE) | 0.58 (0.46–0.72) | 72/397 (18.1) | 120/397 (30.2) | 77/396 (19.4) | 325/396(82.1) | 299/325(92.0) |
Chemotherapy Q3W | 400 | 17 (14.3–22) | 16/400 (4.0) | 44/400 (11.0) | 78/399 (19.5) | 317/399(79.4) | 266/317(84.0) | ||||
Cascone 2022 | NCT03158129 (2017) | II | Ipilimumab plus nivolumab plus Chemotherapy | 22 | NR | NR | 4/22 (18.2) | 11/22 (50.0) | 4/22 (18.0) | 20/22(91.0) | 19/20(95.0) |
Nivolumab plus Chemotherapy | 22 | NR | 4/22 (18.2) | 7/22 (32.1) | 10/22(45) | 22/22(100) | 20/22(91.0) | ||||
Yue 2023 | NCT04379635 (2020) | III | Tislelizumab Q3W plus Chemotherapy Q3W | 226 | NR(NE-NE) | 0.56(0.40–0.79) | 92/226(40.7) | 127/226 (56.2) | 157/226(69.5) | 190/226(84.1) | NR |
Chemotherapy Q3W | 227 | NR(16.6-NE) | 13/227 (5.7) | 34/227 (15.0) | 148/226 (65.5) | 173/227(76.2) | NR | ||||
Cascone 2023 | NCT04025879 (2019) | III | Nivolumab Q3W plus Chemotherapy Q3W | 229 | NR(28.9-NE) | 0.58(0.42–0.81) | 58/229(25.3) | 81/229(35.4) | 66/194 (34.0) | 178/229(77.7) | 159/178(89.0) |
Chemotherapy Q3W | 232 | 18.4 (13.5–28.1) | 11/232(4.7) | 28/232(12.1) | 55/205 (27.0) | 178/232(76.6) | 161/178 (90.0) |